How toxic is ibogaine?

Litjens and colleagues frame ibogaine as a psychoactive indole alkaloid derived from the root bark of Tabernanthe iboga, historically used in West Africa and sporadically studied since its isolation in 1901. Interest in its alleged anti-addictive properties grew after anecdotal reports in the 1960s and subsequent patents claiming single-dose reductions in addictive behaviours. Despite a rise in use among people seeking treatment for substance-use disorders, the authors note that human research remains limited and reports of serious adverse events have raised safety concerns. This review sets out to synthesise available evidence on ibogaine’s pharmacokinetics and pharmacodynamics, its putative mechanisms of action, and reported toxicities in animals and humans. The stated aim is to clarify how ibogaine and its principal metabolite noribogaine behave biologically and to assess the clinical risks associated with their use, particularly cardiotoxicity and neurotoxicity, given increasing unsupervised use by alternative therapists and individuals with substance-use disorders.

The study is a narrative review based on a structured search of PubMed using the keywords “ibogaine” and “noribogaine” together with a set of topic filters including mechanism of action, pharmacokinetics, pharmacodynamics, neurotransmitters, toxicology, cardiac, neurotoxic, human data, animal data, addiction, withdrawal, death and fatalities. The searches returned 382 unique references, of which 156 related to human data and 38 to toxicology in animals and humans. From the identified literature the investigators extracted clinical and toxicological case reports and located 14 original case reports of interest. Four forensic case reports were excluded because they lacked reliable clinical-course information or clear cause-of-death data. The methods emphasise inclusion of both animal and human data to address pharmacology and reported adverse events, but the extracted text does not provide a formal quality assessment or quantitative meta-analytic methods.

Pharmacokinetics: Ibogaine is primarily metabolised to noribogaine (10-hydroxyibogamine) mainly by CYP2D6, with CYP2C9 and CYP3A4 contributing. Noribogaine appears rapidly in blood (within 15 minutes after ibogaine) and has a substantially longer elimination half-life than the parent drug: a half-life of 7.45 hours was reported for ibogaine in CYP2D6 extensive metabolisers, whereas noribogaine’s mean plasma elimination ranged from 28 to 49 hours across dose groups in a human volunteer study. Both compounds are highly lipophilic and accumulate in brain and fat; post-mortem data in one case showed very high tissue concentrations and an unusually high ibogaine:noribogaine ratio, possibly reflecting slow CYP2D6 metabolism. Mechanisms of action: The paper reports that ibogaine and noribogaine act on multiple neurotransmitter systems rather than a single dominant target. They show micromolar affinity for NMDA receptors and for kappa- and mu-opioid receptors, and interact with cholinergic, serotonergic and dopaminergic systems. Molecular effects cited include altered expression of substance P, brain-derived neurotrophic factor (BDNF), c-fos and egr-1, and an increase in glial cell line-derived neurotrophic factor (GDNF) transcription in midbrain regions such as the ventral tegmental area (VTA), which the authors link to possible restoration of dopaminergic function related to addiction. Experimental neurotoxicity: In rodents, high doses of ibogaine produce neurodegeneration of cerebellar Purkinje cells, probably mediated by inferior-olive stimulation and excitotoxicity. Studies cited report Purkinje-cell degeneration after intra-peritoneal doses of 50–100 mg/kg and above, whereas single doses of 25–40 mg/kg did not show neurotoxicity in the assays described. Tremors and signs consistent with olivo-cerebellar stimulation were common in animals; tremor phenotypes were short-lived and may reflect ibogaine rather than noribogaine activity. The authors note suggestions that noribogaine may be less neurotoxic than ibogaine, and also report an experimental finding that the LD50 for noribogaine in mice was 2.4 times lower than that for ibogaine, a point presented without resolution of the apparent contradiction. Human neurological effects: Human data are limited and heterogenous. In open-label administrations (examples include fixed doses of 500, 600 or 800 mg in one trial), early nausea and mild tremors were frequently reported. Case reports document neurological events such as ataxia, muscle spasms, tonic–clonic seizures, encephalopathy, prolonged visual or cognitive deficits in some patients, and transient psychotic or manic episodes in a small series. In two cases the authors of the reports attributed severe neurological deficits to hypoxia during ibogaine-induced respiratory depression and coma; overall, it remains unclear whether ibogaine causes direct long-term neurotoxicity in humans at therapeutic dosages. Cardiac toxicity and fatalities: Cardiovascular effects recorded in humans include transient increases in blood pressure and decreases in pulse 1–5 hours after doses of 10–25 mg/kg. The review compiles reports of approximately 27 fatalities associated with ibogaine or iboga ingestion. A forensic series described 19 fatalities in detail, with at least 9 cases attributed to cardiotoxicity (including cardiomyopathy, myocardial infarction, arrhythmias and cardiac hypertrophy); several victims had known pre-existing cardiac disease. Notably, multiple fatalities occurred many hours to days after ingestion, prompting the suggestion that the longer-lived metabolite noribogaine may contribute to delayed cardiac events. A well-documented case is highlighted in which a woman who ingested about 3.5 grams of 15% iboga extract developed a markedly prolonged corrected QT interval of 616 ms (the QT interval is the electrocardiographic time from onset of ventricular depolarisation to the end of repolarisation) and ventricular tachyarrhythmias; her QT normalised at 42 hours and she survived. Many other case reports describe QT prolongation and ventricular arrhythmias in individuals without known pre-existing cardiac disease or family history. By contrast, open-label trials often reported acceptable tolerability; the investigators propose that dose differences (case-report doses frequently exceeded 2 g, while trials used 500–800 mg or much lower doses in pharmacokinetic studies) and uncertainty about preparation/purity likely explain this discrepancy. Mechanistic electrophysiology: Koenig and colleagues are cited as demonstrating that ibogaine blocks the cardiac ether-a-go-go-related gene (hERG) potassium channel, which is central to ventricular repolarisation; hERG blockade delays repolarisation, prolongs the QT interval and can precipitate torsades de pointes and sudden cardiac death. Ibogaine was also shown to inhibit human ventricular sodium and calcium currents, effects that would further prolong cardiac repolarisation. Drug–drug interactions: The review emphasises that concomitant substances may contribute to risk. Benzodiazepines, methadone and buprenorphine have been detected in decedents. CYP2D6 polymorphism substantially affects concentrations of ibogaine and noribogaine; a study of healthy volunteers pretreated with the CYP2D6 inhibitor paroxetine showed approximately a two-fold increase in the combined active moiety (ibogaine plus noribogaine). The authors note recommendations that CYP2D6 poor metabolisers should receive reduced doses and flag interactions with CYP3A4 substrates such as buprenorphine as potentially slowing ibogaine clearance.

Litjens and colleagues interpret the assembled evidence as indicating that ibogaine and its metabolite noribogaine have complex pharmacology with actions across multiple neurotransmitter systems and persistent systemic exposure to noribogaine. They highlight cardiotoxicity via hERG channel blockade and inhibition of cardiac sodium and calcium currents as a plausible and mechanistically supported explanation for QT prolongation, ventricular arrhythmias and a subset of ibogaine-associated fatalities. The authors position their findings against earlier literature by noting a contrast between the acceptable tolerability reported in some open-label trials and accumulating case reports of severe cardiotoxic events; they attribute this partly to differences in dose and product purity, and partly to under-recognition of delayed effects mediated by noribogaine. Animal studies demonstrate dose-dependent cerebellar neurodegeneration, but the relevance of these findings to humans remains uncertain because of species differences, variable dosing and limited neuropathological evidence in human cases. Key limitations acknowledged include the scarcity of controlled human data, reliance on case reports and forensic series with variable completeness, and heterogeneity in dosing and formulation of compounds used (purified ibogaine hydrochloride versus crude extracts). The authors also note the difficulty of separating direct drug effects from complications such as respiratory depression, hypoxia, or concomitant drug use in some reports. In terms of implications, the review recommends caution: individuals with pre-existing cardiac disease or those taking concurrent medications metabolised by CYP2D6 or CYP3A4 appear at heightened risk. Continuous electrocardiographic monitoring and extended post-ingestion observation are suggested by the authors, and they draw attention to culturally embedded practices (for example, a 3-day observation period after ritual iboga use in Gabon) aimed at reducing stress-induced sympathetic stimulation during vulnerable periods. The authors conclude that unsupervised or poorly supervised use of ibogaine-containing preparations remains hazardous and that further ibogaine-related deaths are likely without safer clinical frameworks and better characterisation of risks.

Alternative therapists and people seeking to self-treat substance dependence continue to use iboga extracts, root scrapings and ibogaine hydrochloride. Given limited understanding of the pharmacology of crude extracts and purified ibogaine, variable dosing and often limited medical supervision, these practices are described as risky experiments. The authors conclude that ibogaine-related fatalities are likely to continue, especially among those with pre-existing cardiac conditions and those taking concomitant medications that affect ibogaine metabolism.